News Search Results
Oct 20, 2025, 08:30 ET Driving Success in Therapeutics with Recombinant Antibody Production, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Oct 20, 2025, 08:30 ET From Signals to Strategy: The Next Chapter of Digital Biomarkers, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Oct 20, 2025, 08:25 ET Anixa Biosciences Announces Issuance of Chinese Patent Covering Breast Cancer Vaccine Technology
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the Chinese National Intellectual Property Administration (CNIPA)
More news about: Anixa Biosciences, Inc.
Oct 20, 2025, 07:00 ET HanchorBio Showcases Pipeline Momentum with HCB101 and HCB301 Data Across Five Major Oncology Meetings in Q4 2025
SAN FRANCISCO, Oct. 20, 2025 /PRNewswire/ -- HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company developing next-generation immunotherapies, today announced that new clinical data from HCB101, its differentiated, engineered SIRPα-Fc
More news about: HanchorBio Inc.
Oct 20, 2025, 07:00 ET Leap Therapeutics Presents Final Data from DeFianCe Study at ESMO 2025
CAMBRIDGE, Mass., Oct. 20, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced final results from Part B of the DeFianCe study (
More news about: Leap Therapeutics, Inc.
Oct 20, 2025, 06:55 ET Protocatechuic Acid Market worth $24.0 million by 2030 - Exclusive Report by MarketsandMarkets™
skin-protective capabilities are increasingly utilized in the booming personal care and cosmetics sector. Moreover, technological advancements in biotechnology and green chemistry are enabling more sustainable and cost-effective production processes, thereby strengthening PCA's position as a vital ingredient
More news about: MarketsandMarkets
Oct 20, 2025, 06:13 ET Groundbreaking Study in the Journal of Clinical Investigation Advances Cell Therapy for Huntington's Disease Treatment
therapies against neurodegenerative disorders." [About Unixell Biotechnology] Shanghai Unixell Biotechnology, founded in 2021, focuses on developing cell therapies for neurological diseases such as Parkinson's disease
More news about: UniXell Biotechnology
Oct 20, 2025, 05:00 ET FDA Grants Orphan Drug Designation to Cellenkos' CK0803 Tregs for Treatment of Amyotrophic Lateral Sclerosis
HOUSTON, Oct. 20, 2025 /PRNewswire/ -- Cellenkos® Inc., a clinical-stage biotechnology company focused on developing allogeneic, off-the-shelf, T regulatory (Treg) cell therapies for autoimmune diseases and inflammatory disorders especially
More news about: Cellenkos, Inc.
Oct 20, 2025, 03:41 ET AgiBot Shines at GITEX GLOBAL 2025, Developing Comprehensive Humanoid Solutions and Connecting Intelligent Future
edition, GITEX GLOBAL stands as the world's most established and iconic large-scale tech exhibition exploring breakthroughs in AI, quantum computing, biotechnology and sustainable technology that are transforming global infrastructure and growth. Built on the foundation of robot ontology
More news about: AgiBot Innovation (Shanghai) Technology Co.,Ltd.
Oct 19, 2025, 20:10 ET Ascletis Completes Enrollment in U.S. Phase IIa Study for Its Once-Monthly Subcutaneous Depot Treatment Formulation of Small Molecule GLP-1R Agonist ASC30 for Obesity
About Ascletis Pharma Inc. Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases.
More news about: Ascletis Pharma Inc.
Oct 19, 2025, 19:00 ET Clover Appoints Nicholas Jackson, Ph.D., as President of Global R&D and Alliances
Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, today announced the appointment
More news about: Clover Biopharma
Oct 19, 2025, 17:15 ET CLARINS & V MAGAZINE CELEBRATE HIGH-PERFORMANCE BEAUTY WITH A STAR-STUDDED GOLDEN HOUR EVENT IN AUSTIN
smooths, and brightens in just 30 seconds. Formulated with a retinol-like technology combining botanical actives with the latest advancements in biotechnology for instant, high-performance results. Guests enjoyed a cocktail hour bathed in golden light inspired by Double Serum's signature
More news about: Clarins USA
Oct 19, 2025, 10:49 ET iOncologi Secures Foundational U.S. Patent as Landmark Studies Link COVID19 mRNA Vaccines to Improved Survival with Cancer Immunotherapy
GAINESVILLE, Fla., Oct. 19, 2025 /PRNewswire/ -- iOncologi, Inc., a biotechnology company developing next-generation RNA-based cancer immunotherapies, today announced that the United States Patent and Trademark Office (USPTO)
More news about: iOncologi, Inc.
Oct 19, 2025, 08:45 ET SystImmune Announces iza-bren Meets One of the Dual Primary Endpoints in the BL-B01D1-303 Trial in Recurrent or Metastatic NPC Patients with Results Presented as a Late-Breaking Oral Presentation at ESMO
REDMOND, Wash., Oct. 19, 2025 /PRNewswire/ -- SystImmune Inc. (SystImmune), a clinical-stage biotechnology company, today announced positive topline results from the BL-B01D1-301 trial. The trial has met one of the dual primary endpoints (BICR-assessed
More news about: SystImmune, Inc.
Oct 18, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Jasper Therapeutics, Inc. and Certain Officers - JSPR
here for information about joining the class action] Jasper, a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria ("CSU"), Chronic Inducible
More news about: Pomerantz LLP
Oct 18, 2025, 01:00 ET SCG announces presentation of clinical results of SCG142 in patients with HPV-related carcinoma at ESMO 2025
SINGAPORE, Oct. 18, 2025 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company developing next-generation immunotherapies for infectious diseases and their associated cancers, announced the presentation of first-in-human
More news about: SCG Cell Therapy Pte Ltd
Oct 18, 2025, 01:00 ET SCG announces presentation of clinical results of SCG142 in patients with HPV-related carcinoma at ESMO 2025
SINGAPORE, Oct. 18, 2025 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company developing next-generation immunotherapies for infectious diseases and their associated cancers, announced the presentation of first-in-human
More news about: SCG Cell Therapy Pte Ltd
Oct 17, 2025, 17:42 ET aTyrPharma, Inc. Stockholders with Large Losses are Encouraged to Contact Robbins LLP for Information About the Class Action Against ATYR
DIEGO, Oct. 17, 2025 /PRNewswire/ -- Company: aTyrPharma, Inc. (NASDAQ: ATYR) is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation.
More news about: Robbins LLP
Oct 17, 2025, 16:00 ET FDA APPROVES TEZSPIRE® FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing
More news about: Amgen
Oct 17, 2025, 10:40 ET Sterile Dry Powder Active Pharmaceutical Ingredient (API) Market is expected to generate a revenue of USD 6.48 Billion by 2032, Globally, at 8.2% CAGR: Verified Market Research®
(Major Depression Drug, Generalized Anxiety Disorder Drug, Fibromyalgia Drugs, Neuropathic Pain Medication), By Application (Pharmaceutical and Biotechnology Industries, Hospital), By Geographic Scope And Forecast
More news about: Verified Market Research
Oct 17, 2025, 10:37 ET Wobble Genomics Presents Latest Data at ESMO: establishing the robustness of an enhanced liquid biopsy platform for sensitive detection of low-abundance RNA
EDINBURGH, England, Oct. 17, 2025 /PRNewswire/ -- Wobble Genomics, a biotechnology company working to improve outcomes in cancer through better diagnosis and therapy selection, via a novel ultra-sensitive cell-free RNA (cfRNA)
More news about: Wobble Genomics
Oct 17, 2025, 10:16 ET Syngene International invests in dedicated peptide laboratory and advanced automation
(NSE: SYNGENE) (ISIN: INE 398R01022) is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. Syngene's team of over 5,600 scientists brings both deep expertise and
More news about: Syngene International
Oct 17, 2025, 10:00 ET SystImmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results of Iza-bren, an EGFR x HER3 Bispecific Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors at ESMO 2025
Wash. and PRINCETON, N.J., Oct. 17, 2025 /PRNewswire/ -- SystImmune Inc. (SystImmune), a clinical-stage biotechnology company, and Bristol Myers Squibb (NYSE: BMY) today announced the oral presentation of the first disclosure of the safety and efficacy data from
More news about: SystImmune, Inc.
Oct 17, 2025, 09:50 ET Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation
toxicity compared to conventional chemotherapy. GT Biopharma, Inc. (NASDAQ: GTBP) is a clinical-stage biotechnology company headquartered in San Francisco that's focused on harnessing the power of the immune system to fight cancer. The firm is currently advancing
More news about: Equity Insider
Oct 17, 2025, 09:00 ET Precision Oncology Approaches Drive $312B Market Transformation
established immunotherapy platforms4. GT Biopharma, Inc. (NASDAQ: GTBP) is a clinical-stage biotechnology company headquartered in San Francisco that's focused on harnessing the power of the immune system to fight cancer. The firm is currently advancing
More news about: USA News Group